Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis by Arellano-Orden, Elena et al.
 Clinical Investigations 
 Respiration 2013;86:201–209 
 DOI: 10.1159/000342042 
 Small Particle-Size Talc Is Associated with 
Poor Outcome and Increased Inflammation in 
Thoracoscopic Pleurodesis 
 Elena Arellano-Orden a, c    Auxiliadora Romero-Falcon c    José Martin Juan c    
Manuel Ocaña Jurado b    Francisco Rodriguez-Panadero a, c, d    
Ana Montes-Worboys a, c, d 
 a  Instituto de Biomedicina de Sevilla,  b  Instituto de Ciencia de Materiales de Sevilla,  c  Unidad Médico-Quirúrgica 
de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio,  Sevilla , and  d  CIBER de Enfermedades 
Respiratorias, I.S. Carlos III,  Madrid , Spain
 
after talc) occurred in 8 of 103 patients in the ST and in 1 of 
124 in the ‘large-particle talc’ group (p = 0.007). Patients who 
received ST had significantly higher proinflammatory cyto-
kines in pleural fluid and serum after talc application, and 
also in supernatants of the in vitro study. Pleural tumor bur-
den correlated positively with proinflammatory cytokines in 
serum, suggesting that advanced tumor states induce stron-
ger systemic reactions after talc application.  Conclusions: ST 
provokes a strong inflammatory reaction in both pleural 
space and serum, which is associated with a higher rate of 
early deaths observed in patients receiving it. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Talc is widely accepted as the agent of choice for 
pleurodesis in malignant pleural effusions (MPE), but 
there is concern about possible complications, especially 
acute respiratory distress, systemic inflammation and 
extrapleural dissemination of particles  [1–5] . It is now es-
tablished that talc containing small particles is associated 
with more complications  [6–10] , but there are still some 
open questions.
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 Abstract 
 Rationale: Talc is very effective for pleurodesis, but there is 
concern about complications, especially acute respiratory 
distress syndrome.  Objectives: It was the aim of this study to 
investigate if talc with a high concentration of small particles 
induces greater production of cytokines, and if pleural tu-
mor burden has any influence on the local production and 
spillover of cytokines to the systemic circulation and even-
tual complications.  Methods: We investigated 227 consecu-
tive patients with malignant effusion submitted to talc 
pleurodesis. One hundred and three patients received 
‘small-particle talc’ (ST; containing about 50% particles  ! 10 
  m) and 124 received ‘large-particle talc’ (with  ! 20% parti-
cles  ! 10   m). Serial samples of both pleural fluid and blood 
were taken before and 3, 24, 48 and 72 h after thoracoscopy. 
Also, mesothelial cells were stimulated with both types of 
talc in vitro.  Measurements and Results: Interleukin-8, tu-
mor necrosis factor-  , vascular endothelial growth factor, 
basic fibroblast growth factor and thrombin-antithrombin 
complex were measured in all samples. Early death ( ! 7 days 
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 (1) According to one report, it appears that not all the 
cases with pulmonary complications associated with talc 
are due to extrapleural dissemination of the particles: in 
1 patient who died 58 h after thoracoscopic talc pleurode-
sis, no extrapleural particles were found at autopsy, but 
acute inflammation was present in both lungs in spite of 
unilateral pleurodesis, and the authors suggested that 
pleural inflammation may trigger pulmonary inflamma-
tion through paracrine and circulating factors without 
actual extrapleural talc dissemination  [11] . If a transfer of 
proinflammatory mediators occurs between the pleural 
space and either the lung or the systemic circulation after 
intrapleural talc application, the question arises as to 
whether a pleural thickening caused by tumor (‘tumor 
burden’) or fibrosis would block that transfer to some de-
gree. Would tumor burden in the pleural space have any 
influence on the local production of cytokines and the 
eventual spillover to the lung following talc pleurodesis? 
 (2) Does talc with a high concentration of small par-
ticles induce a greater production of cytokines in the 
pleural space and in serum?
 (3) Is there any transfer of proinflammatory mediators 
from the pleural space into the systemic circulation? 
 (4) Are high and persistent levels of proinflammatory 
cytokines in serum associated with more complications, 
as suggested by some experimental animal studies  [12, 
13] ?
 Aiming to answer these questions, we have studied 
two sequential series of patients with MPE who were sub-
mitted to thoracoscopic talc pleurodesis using two differ-
ent types of talc in our institution. We hypothesized that 
the severe adverse effects of talc and the different behav-
ior of mesothelial cells would be related to the size of talc 
particles and to changes in the release of proinflamma-
tory cytokines, growth factors and coagulation media-
tors in peripheral venous blood after intrapleural applica-
tion of talc. We also aimed to study the role of these two 
types of talc in an in vitro model of human mesothelial 
cells.
 Materials and Methods 
 Study Population 
 From October 1992 to April 2007, 331 patients with MPE were 
submitted to thoracoscopic talc poudrage at our institution, al-
ways following the same protocol  [14] : thoracoscopy was per-
formed in the respiratory endoscopy suite by the same physicians 
in all cases, using local anesthesia (mepivacaine) plus intravenous 
analgesia (pethidine). Tumor burden in the pleural space was 
evaluated in every case following a rating method previously pub-
lished by our group  [15] . After complete removal of the fluid and 
pleural biopsies taken, 5 g of asbestos-free, sterile talc was used in 
every case. From the 331 patients submitted to talc pleurodesis, we 
selected only the ones who had a positive thoracoscopic biopsy 
with identification of the type of tumor in the pleura (n = 227). 
Among them, 103 received talc purchased from the Instituto Es-
pañol TM (Seville, Spain) that will be referred to as ‘small-particle 
talc’ (ST) in the present article. When a new talc was available at 
our institution, another 124 patients were treated with Steritalc  
(Novatech, La Ciotat, France) that will be referred to as ‘large-
particle talc’ (LT) ( table 1 ). All talc samples had undetectable lev-
els of endotoxin as determined with the Limulus Amebocyte Ly-
sate assay (Sigma GmbH, Germany).
 Talc Particle Studies 
 Scanning electron microscopy, distribution of particle size 
and mineralogical and chemical composition (crystal phases) 
studies were performed at the Instituto de Ciencia de Materiales 
(University of Seville, Spain) (online supplementary material, 
www.karger.com/doi/10.1159/000342042).
 Clinical Data Collection 
 Besides demographic data, all complications were systemati-
cally recorded in every patient. The outcome of pleurodesis, ac-
cording to criteria described in the European Respiratory Society/
American Thoracic Society consensus statement  [16] , was also re-
corded, and all patients were followed until death or for a period 
 6 4 years after talc poudrage. Pleurodesis was considered as failed 
if there was a relapse of the effusion at any time during the whole 
follow-up period.
Table 1.  Baseline characteristics of patients in each group (no sig-
nificant differences)
Global
series
(n = 227)
ST
(n = 103)
LT
(n = 124)
Mean age 8 SEM,
years 60.3680.8 60.681.2 60.181.1
Males/females 112/115 55/48 59/65
Karnofsky
Normal 162 (71.4) 81 (78.6) 81 (65.3)
Self-care 63 (27.7) 20 (19.4) 43 (34.7)
Disabled 2 (0.9) 2 (2) 0
Origin of tumors 
Breast 57 (25.1) 26 (25) 31 (25)
Lung 56 (24.7) 21 (20.5) 35 (28)
Mesothelioma 38 (16.7) 16 (16) 22 (17)
Lymphoma 15 (6.6) 9 (8.7) 6 (4.8)
Ovary 11 (4.8) 4 (3.9) 7 (5.6)
Colon 12 (5.3) 6 (5.8) 6 (4.8)
Kidney 12 (5.3) 6 (6.8) 6 (4.8)
Other 26 (11.5) 15 (13.3) 11 (10)
Figures in parentheses are percentages.
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 Biological Studies ex vivo 
 Serial blood and pleural fluid samples were obtained from ev-
ery patient and then centrifuged and the supernatants frozen just 
before thoracoscopy (baseline) and at 3, 24, 48 and 72 h following 
talc pleurodesis. All patients were informed that those samples 
may be used in the future for research and publication, and all 
agreed to participate and gave written informed consent. This 
study was approved by the local ethics committee of our institu-
tion. Interleukin (IL)-8, tumor necrosis factor (TNF)-  , vascular 
endothelial growth factor (VEGF) and basic fibroblast growth 
factor (bFGF) were measured in all samples by ELISA (Quanti-
kine, R&D Systems, Minneapolis, Minn., USA), and the throm-
bin-antithrombin complex (TAT) was determined with the En-
zygnost TAT kit (Dade Behring, Germany).
 Cell Culture Study: Coincubation of Talc with Mesothelial 
Cells in vitro 
 The mesothelial cell line Met-5A was incubated with 4   g/cm 2 
(according to previous reports)  [17] of the same two types of talc 
used in patients – as described above – during 24 h, and then IL-8 
levels were determined at different time points in supernatants 
afterwards (online suppl. material).
 Statistical Analysis 
 Statistical analysis was performed using SPSS version 15 soft-
ware (SPSS Inc., Chicago, Ill., USA). Results were considered sig-
nificant when p  ! 0.05. Non-parametric tests were used when data 
did not show a normal distribution. In order to have clear infor-
mation on the individual response to talc, we calculated the incre-
ment (fold) – defined as the ratio between the levels obtained after 
talc and at baseline – for each marker.
 Results 
 Talc Analyses 
 According to X-ray diffraction (data not shown), our 
samples were pure talc [Mg 3 Si 4 O 10 (OH) 2 ], free of asbestos 
(absence of fibers) ( fig. 1 )  and of other significant impuri-
ties (online suppl. table E1). Average (mean) and median 
diameters of particles, as well as the 10 and 90% percen-
tile ranks obtained from the volumetric size distribution 
curves are described in  table 2 .
 Clinical Results 
 Acute pain or transient dyspnea in the first 15 min af-
ter talc application was observed in 16.5% of patients in 
the ST group and in 18.5% in the LT group (no significant 
differences).
 We observed thrombotic events in 4.9% of the patients 
who received ST and in 1.6% of those receiving LT. De-
spite the tendency to a higher rate in the ST group, there 
were no statistically significant differences.
 Pleurodesis was completely successful in 73.7% of the 
patients in the ST group and in 70.2% in the LT group, 
with no significant differences ( table 3 ).
 Survival and Early Death after Talc Pleurodesis 
 The median survival was shorter in the ST group (al-
though it did not reach statistical significance) ( table 3 ). 
 Early death (within 7 days after talc application) occurred 
in 8 of 103 patients in the ST and only in 1 of 124 in the 
LT group (7.8 vs. 0.8%, respectively; p = 0.007) ( table 4 ; 
online suppl. fig. E-5A and E-5B). Causes of early death 
( ! 7 days) in the ST group (8 patients) were: contralateral 
pneumonia (n = 1), hypotension and renal failure (n = 2), 
hyponatremia and coma (n = 1), deep venous thrombosis 
Table 2.  Morphometric analysis of ST and LT
Type of talc D iameter of particles 10–90%
mean 8 SD median
ST, m 15.9813.9 11.5 2.7–35.9
LT, m 25.3816.5 22.8 5.6–48.1
a b
 Fig. 1. Scanning electron microscopy pho-
tographs of ST ( a ; mean 18.5  8 14.2   m) 
and LT ( b ; 25.3  8 16.5   m). 
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and pulmonary embolism (n = 2), acute respiratory fail-
ure (n = 1), and oversedation (n = 1). The cause of early 
death in the LT group was related to problems caused by 
the original tumor (carcinoma of the pancreas, with in-
tractable vomiting and rapid deterioration). The only pa-
tient who developed acute respiratory distress had a 25.8-
fold increase in IL-8 in serum 24 h after talc pleurodesis 
and a 17.8-fold in TAT levels in serum at that same time 
point. Most of the deaths registered between days 8 and 
15 were not related with the type of talc used, but with 
other clinical conditions/complications: prolonged air 
leak (4 cases), cardiogenic pulmonary edema in 4 cases 
(associated with ischemic heart disease), infection associ-
ated with post-chemotherapy neutropenia (1 case), and 
unexplained coma (with negative CT for brain metasta-
ses) in 1 case.
 Survival was negatively correlated with tumor burden 
both in the ST (r = –0.313, p = 0.001) and in the LT group 
(r = –0.241, p = 0.007).
 Relationship between Biological Markers and Clinical 
Data 
 Baseline levels of IL-8 and VEGF in serum were sig-
nificantly higher in patients who died in the first 7 days 
( fig. 2 ). Moreover, we found a close relationship between 
IL-8 baseline values in serum and levels of TAT (r = 0.757, 
p  ! 0.001).
 We found a clear relation between increase in IL-8 in 
pleural fluid and the success of talc pleurodesis. As shown 
in  figure 3 , the group of patients with complete success 
had the highest increment of IL-8. IL-8 mRNA in pleural 
fluid was also higher in successful cases at 24 h after 
pleurodesis. The increments of the other markers studied 
(TNF-  , VEGF, bFGF and TAT) were not significantly 
related to the outcome of pleurodesis.
 Tumor Burden in the Pleural Cavity 
 There were significant differences in tumor burden in 
the pleural cavity when comparing complete success cas-
es with failed ones (4.9  8 0.13 vs. 5.7  8 0.46; p = 0.02) 
(online suppl. fig. E1). Tumor burden correlated positive-
ly with baseline levels of IL-8 in the pleura (r = 0.415, p  ! 
0.001) (online suppl. fig. E2), but it was inversely related 
to increments of IL-8 at 24 and 48 h (p = 0.019 and 0.203, 
respectively) and to IL-8 mRNA in pleural fluid, thus 
suggesting that cases with both high tumor burden and 
baseline levels of IL-8 did not have much capacity to in-
crease IL-8 production after intrapleural application of 
talc. This negative correlation between tumor burden and 
increments of proinflammatory cytokines in the pleural 
space was observed both in the ST and LT groups.
 When levels of proinflammatory cytokines (IL-8 and 
TNF-  ) were considered in serum, we found a positive 
Table 3.  Outcome of pleurodesis
Global results Total ST
( n = 76)
LT
(n = 104)
p value
Complete success 129 (71.7) 56 (73.7) 73 (70.2) NS
Partial success 32 (17.8) 14 (18.4) 18 (17.3) NS
Failure 19 (10.5) 6 (7.9) 13 (12.5) NS
Mean tumor burden in parietal pleura 8 SEM (range 0–3) 2.280.07 2.280.06 NS
Mean tumor burden in visceral pleura 8 SEM (range 0–3) 1.680.08 1.680.07 NS
Mean survival 8 SEM, months 13.681.6 16.383.1 11.381.3 NS
Median survival, months 5.2 [0.03–153.4] 4.4 [0.03–153.4] 7 [0.13–70.6] NS
Figures in parentheses are percentages; figures in brackets are ranges. The 2 test was used for statistical analysis. Those patients 
who died before 30 days following talc application were considered as ‘non-evaluable’ regarding the outcome of pleurodesis. Therefore, 
180 patients were finally evaluable for results of pleurodesis. NS = Not significant.
Table 4.  Patients who died before 7, 15 or 30 days after talc 
pleurodesis
Death
<7 days
Death
<15 days
Death
<30 days
ST 8 (7.8) 12 (11.7) 27 (26.2)
LT 1 (0.8) 7 (5.6) 20 (16.1)
p value 0.007 0.1 0.062
F igures in parentheses are percentages. The 2 test was used 
for statistical analysis.
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correlation with tumor burden in the parietal pleura at 
several time points. Regarding visceral pleura, correla-
tion was also positive with serum levels of IL-8 and incre-
ments of TNF-  at 24 h (lower than in parietal pleura). 
Those findings suggest that advanced tumor states would 
favor stronger systemic reactions after intrapleural appli-
cation of talc. In support of this, we found a strong posi-
tive correlation between tumor burden in the parietal 
pleura and IL-8 mRNA expression in serum 72 h after 
talc pleurodesis (p = 0.012). Our results suggest that – if 
there is any transfer between the pleural space and sys-
temic circulation – the parietal pleura would play a pre-
dominant role.
 Comparison of Biological Markers in Pleural Fluid 
and Serum in Patients Receiving the Two Types of Talc 
 When we compared the production of IL-8, TNF-  , 
VEGF and bFGF in pleural fluid and serum from patients 
submitted to pleurodesis with ST and LT, we found sig-
nificant differences between them ( table 5 ). In most cases, 
ST samples showed higher absolute levels and increments 
of cytokines when compared with samples from patients 
receiving LT. Although the TNF-  levels in the serum 
were higher in the LT group at baseline, the increments 
at 3 and 24 h following intrapleural talc application were 
markedly greater in the ST group, and they were also di-
rectly related to tumor burden in the parietal pleura (p = 
0.005). Increments of TNF-  in serum correlated closely 
with increments of that marker in pleural fluid at 3 and 
24 h after intrapleural talc application (p  ! 0.001 for both 
time points) (online suppl. fig. E3). Correlation between 
increment of IL-8 in serum and pleural fluid was also 
found at 24 h, although with lower significance (p = 0.04).
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 Fig. 2.  a Comparison of baseline levels of IL-8 (pg/ml) in serum of patients surviving  ! 7 and  1 7 days.  b Com-
parison of basal levels of VEGF (pg/ml) in serum of patients surviving  ! 7 and  1 7 days. 
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 Fig. 3. Increment of IL-8 in pleural fluid at 3 h following talc ap-
plication and outcome of pleurodesis. Cases with complete suc-
cess had significantly increased IL-8 in pleural fluid, as compared 
to those with complete or partial failure. NS = Not significant. 
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 Although we found significantly higher levels of VEGF 
in pleural fluid samples from patients receiving ST, there 
were no significant differences in the increments versus 
baseline values, nor significant differences in serum val-
ues. Levels of bFGF did not show any significant differ-
ences between groups in pleural fluid, but they were sig-
nificantly higher in the serum for the ST compared with 
the LT group at 3 and 24 h following intrapleural applica-
tion of talc (17 and 24 pg/ml in ST vs. 4.3 and 7.2 pg/ml 
in LT; p = 0.01 and 0.038, respectively). As with other cy-
tokines, these high levels in serum might contribute to 
the higher rate of complications observed in the ST group 
in our study.
 TAT levels were significantly higher in serum for the 
ST versus the LT group at 24, 48 and 72 h (606, 661 and 
317   g/ml in the ST group vs. 224, 194 and 55   g/ml in 
the LT group; p  ! 0.001, p  ! 0.001 and p = 0.019, respec-
tively) (online suppl. fig. E4), which might be related to 
the higher rate of thrombotic events observed in the ST 
group.
 Response of Mesothelial Cell Lines to Different Types 
of Talc 
 Once we analyzed the in vivo response of two different 
types of talc, we further studied the inflammatory re-
sponse in an in vitro model of human mesothelial cell 
culture treated with the same types of talc.
 We found that both talc types (ST and LT) stimulated 
the mesothelial cell line by releasing higher levels of IL-8 
as compared to the controls. When we compared the re-
sponse to both types of talc, we observed that the ST pro-
voked higher inflammatory response for each time point 
compared to LT ( fig. 4 ), and these results were in agree-
ment with those found in the in vivo study.
 Discussion 
 Talc is certainly inexpensive and highly effective as a 
sclerosing agent. However, its intrapleural administra-
tion can induce acute respiratory distress syndrome  [18] . 
a Differences regarding IL-8 in pleural fluid and serum
Cytokines, pg/ml ST LT p 
mean SEM mean SEM
Pleural IL-8
Baseline 1,291 219 1,083 195 0.478 
3 h 13,835 3,405 5,052 705 0.009 
24 h 27,323 6,541 6,251 804 0.000 
48 h 23,467 6,498 6,846 879 0.005 
72 h 26,151 17,377 5,498 729 0.066 
Fold IL-8 in pleural fluid
3 h vs. baseline 106 41.6 36 7.4 0.088 
24 h vs. baseline 163 53 48 9.9 0.016 
48 h vs. baseline 162 66.6 62 18 0.107 
72 h vs. baseline 41 14.5 13 3.1 0.010 
IL-8 in serum
Baseline 184 61.8 56.9 22.2 0.040 
3 h 92 24 25 3.6 0.014 
24 h 152 49 46 10 0.037 
48 h 241 186 53 18 0.277 
72 h 39 9.9 108 70 0.474 
Fold IL-8 in serum
3 h vs. baseline 1.99 0.6 1.5 0.4 0.483 
24 h vs. baseline 2.5 0.7 2.7 0.5 0.774 
48 h vs. baseline 9.5 7.5 2.2 0.6 0.278 
72 h vs. baseline 1.4 0.4 6.3 2.5 0.182 
b Differences regarding TNF- in pleural fluid and serum
Cytokines, pg/ml S T LT p
mean SEM mean  SEM
Pleural TNF- in pleural fluid
Baseline 9.9 2.7 8.4 1.3 0.607
3 h 105 20.7 42 8.5 0.003
24 h 98 25.1 47 6.7 0.027
48 h 75 23.3 157 118 0.544
72 h 42 11 258 211 0.499
Fold TNF- in pleural fluid
3 h vs. baseline 59 16.0 13 2.5 0.002
24 h vs. baseline 41 12.2 15 3.9 0.024
48 h vs. baseline 42 20.8 129 118 0.524
72 h vs. baseline 4.6 1.1 232 212 0.478
TNF- in serum
Baseline 2.6 0.5 5.4 1.1 0.033
3 h 2.6 0.4 4.2 0.8 0.084
24 h 3 0.5 6.3 1.1 0.007
48 h 3.8 0.5 10 3.6 0.079
72 h 5 1.4 6.7 2.4 0.617
Fold TNF- in serum
3 h vs. baseline 99 20.7 34 8.5 0.002
24 h vs. baseline 91 23.9 38 6.3 0.015
48 h vs. baseline 2.2 0.4 4.6 2.5 0.349
72 h vs. baseline 3.4 1.4 5.1 2.5 0.641
Table 5.  Differences in proinflammatory cytokines in both pleural fluid and serum samples from patients receiving two types of talc 
(delta values were calculated by dividing actual values of cytokines at different time points by those values obtained at baseline)
Sig nificant differences are given in italics.
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The systemic spillover of proinflammatory cytokines 
from the pleural space has been reported as a possible 
cause of the acute respiratory distress syndrome  [11] , in 
addition to the possible extrapleural dissemination of talc 
particles. Werebe and coworkers  [8] found talc crystals in 
distant organs from rats submitted to talc pleurodesis, 
but Fraticelli et al.  [9] did not find extrapleural dissemi-
nation when using talc of larger particle size. Experimen-
tally, Ferrer et al.  [6] demonstrated in rabbits that the in-
trapleural injection of talc with small particles ( ! 10   m) 
elicits greater pulmonary and systemic talc particle depo-
sition compared to LT. Maskell and coworkers  [7] found 
acute inflammation of the lung parenchyma (including 
the contralateral side to the side of pleurodesis) after ran-
domized administration of talc of varying size in humans 
and concluded that the routine use of ‘graded’ talc (in 
which most particles  ! 10   m were removed) would re-
duce the morbidity of this procedure. Moreover, Genofre 
and coworkers  [12] intrapleurally injected talc containing 
small or mixed particles (4.2 vs. 25.4   m average size) in 
rabbits and found talc dissemination in both groups, al-
though there was greater systemic inflammation in the 
small-particle group of animals. However, unspecific sys-
temic inflammation after thoracoscopy can occur even 
without application of talc  [19] , and it could be argued 
that thoracoscopy by itself might have some influence on 
the proinflammation markers in our study. However, the 
same procedure was applied to every patient in both ST 
and LT, and therefore, we believe that the differences ob-
served in our study are mostly related to talc characteris-
tics themselves.
 In our study, we analyzed clinical and biological differ-
ences after thoracoscopic application of both types of talc 
with a high concentration of large or small particles in hu-
mans and, in agreement with previous studies, we found 
important differences in clinical and biological parame-
ters. The two talcs were adequate and similar in chemical 
composition, but they were significantly different in phys-
ical characteristics and in biological response, possibly as-
sociated with the size of the particles. Although the size of 
our ST was larger than the one used by Genofre and co-
workers  [12] in their animal experiments, it is important 
to emphasize that our ST had 50% of particles  ! 11.5   m, 
as compared to the 22.8   m in the LT group (median val-
ues in  table 2 ). Thus, ST about doubles the amount of par-
ticles  ! 10   m when compared with the LT group in our 
study, and this would account for significant differences 
in outcome and inflammation markers. Thus, those par-
ticles with smaller size could be responsible for the side 
effects/complications described in some of our patients.
 One desirable feature for a pleurodesis agent is the in-
duction of an inflammatory response in the pleural space. 
This acute response is mediated by proinflammatory cy-
tokines like IL-8  [20, 21] , and the relation between success 
of pleurodesis and inflammatory response has been ana-
lyzed in our study ( fig. 3 ). We found a clear positive cor-
relation between the increase in pleural IL-8 (which 
means more inflammatory response to talc) and the out-
come of pleurodesis. On the other hand, tumor burden 
was directly correlated with baseline IL-8 levels in the 
pleural space, thus suggesting that inflammatory base-
line states in the pleural space are associated with a heavi-
er tumor burden and a poorer outcome of pleurodesis.
 To our knowledge, this is the first study investigating 
the relationship of tumor burden in the pleural space with 
production of cytokines in pleural fluid and serum, and 
our results support the concept that patients with more 
advanced tumor disease do have a poorer outcome of 
pleurodesis and short survival and have less capacity to 
induce a strong proinflammatory response in the pleural 
space after talc application. On the other hand, there was 
a positive correlation between tumor burden (especially 
in the parietal pleura) and levels of proinflammatory cy-
tokines (IL-8 and TNF-  ) in serum, suggesting that some 
leakage of cytokines might occur from the parietal pleu-
ra (rather than from the visceral one) into the systemic 
circulation. Those findings also suggest that advanced 
tumor states would favor stronger systemic reactions af-
ter intrapleural application of talc.
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 Fig. 4. Levels of IL-8 produced by mesothelial cells at different 
time points after 24 h exposure to 4   g/cm 2 of ST and LT. Cells 
were incubated with talc for 24 h, and then IL-8 levels were deter-
mined at different time points in supernatants afterwards. 
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 Is there any transfer of proinflammatory mediators 
from the pleural space into the systemic circulation? 
There was a striking correlation in the increments of 
TNF-  in serum and pleural fluid at 3 and 24 h following 
intrapleural talc application, and this finding suggests 
that there was a transfer of that cytokine from the pleural 
space into the systemic circulation, and this phenomenon 
appears to be independent of the type of talc used in our 
study. IL-8 correlation was also significant, although to a 
lesser extent.
 As expected, ST provoked a stronger biological re-
sponse than LT, which was supported by our findings in 
vitro. Moreover, we found that ST produces a higher in-
crement of VEGF and TAT in serum samples than LT. 
VEGF is involved in angiogenesis and increases vascular 
permeability, and TAT indicates activation of the coagu-
lation cascade. Our finding of a close correlation between 
IL-8 baseline values in serum and subsequent levels of 
TAT suggests that patients with high levels of this mark-
er at baseline were more prone to develop thrombotic 
events, especially in the ST group.
 The ST group had a higher early death rate than the LT 
group (7.8 vs. 0.8% in the first 7 days, respectively; p = 
0.007). If we assume that talc-associated complications 
occur within the first few days, the clear differences ob-
served between groups is striking in our study ( table 4 ). 
Rather than the characteristics of the population included 
( table 1 ), our study emphasizes that short survival was re-
lated to higher levels of cytokines (especially IL-8) in se-
rum of patients receiving ST. Our group has previously 
demonstrated that IL-8 is involved in the activation of co-
agulation after talc pleurodesis, and it might also be im-
plicated in the early death of patients with MPE  [22] . On 
the other hand, the levels of VEGF and TAT found in the 
serum samples from patients of the ST group would sug-
gest a spillover of the mediators from the pleural cavity to 
the systemic circulation after intrapleural talc application.
 Are high and persistent levels of proinflammatory cy-
tokines in serum associated with more complications? 
We believe that the answer is positive, but the question 
remains open as to whether the systemic use of non-ste-
roid anti-inflammatory drugs would palliate this prob-
lem (probably with some cost on the side of the effective-
ness of pleurodesis).
 Lack of randomization in recruiting patients might in-
troduce a potential bias in our study, especially concern-
ing the rate of complications in each group (the LT group 
was posterior to the ST group), and it could be argued
that both clinical characteristics of the patients and the 
operator’s experience could have some influence on the 
results. However, clinical characteristics of the patients 
were very similar in both groups, as shown in  table 1 . As 
for operator experience, this study was started only after 
280 thoracoscopies (including more than 200 talc pou-
drage procedures) had been performed by the same team. 
We thus believe that the learning curve has little influ-
ence on the results reported in our study.
 A few comments on prolonged air leak in some of our 
patients: in most of the cases, this complication arises 
during lung re-expansion in patients who have under-
gone chemotherapy prior to the pleurodesis procedure, 
and we believe that rupture of some necrotic tumoral 
nodules on the visceral pleura are the main cause of this 
troublesome complication in patients with MPE.
 In conclusion, ST provokes a stronger inflammatory 
reaction in the pleural space, which leads to better results 
in pleurodesis. However, this is associated with shorter 
survival in our patients and with higher levels of proin-
flammatory cytokines in serum and a higher rate of com-
plications. Further studies are needed in order to find the 
talc with ideal – and homogeneous – particle size to sup-
port its use as a safe agent for pleurodesis.
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